GHRH Antagonist Shows Broad Efficacy Against Estrogen Receptor Positive and Negative Breast Cancer
Background
Breast cancer remains a leading cause of cancer-related mortality, with diverse subtypes presenting unique treatment challenges. Estrogen receptor positive (ER+) breast cancer often responds to hormone therapy, but estrogen receptor negative (ER-) breast cancer, including triple-negative breast cancer, is typically more aggressive and lacks targeted treatments. Growth hormone-releasing hormone (GHRH) and its receptors are known to be expressed in various cancers, including breast cancer, and are implicated in tumor growth and progression. However, the potential of targeting GHRH signaling with an antagonist across both ER+ and ER- breast cancer subtypes has not been fully explored, representing a significant knowledge gap in developing broad-spectrum therapeutic strategies.
Results
The GHRH antagonist MZ-4-71 demonstrated significant anti-proliferative effects in both breast cancer cell lines. In ER+ MCF-7 cells, MZ-4-71 reduced cell proliferation by 65% (p<0.001) at a concentration of 100 nM after 72 hours. Similarly, in ER- MDA-MB-231 cells, proliferation was inhibited by 48% (p<0.01) at the same 100 nM concentration. Furthermore, treatment with MZ-4-71 induced a 2.5-fold increase in apoptosis in MCF-7 cells and a 2.1-fold increase in MDA-MB-231 cells at 100 nM (p<0.05 for both). These effects were dose-dependent, with maximal inhibition observed at higher concentrations. > The GHRH antagonist MZ-4-71 significantly reduced cell proliferation and induced apoptosis in both estrogen receptor positive and estrogen receptor negative breast cancer cell lines, indicating a broad therapeutic potential.
Why It Matters
This study highlights a novel therapeutic approach for breast cancer treatment by targeting the GHRH pathway, showing efficacy across both ER+ and ER- subtypes. The ability of MZ-4-71 to inhibit the growth of ER- breast cancer cells, which are notoriously difficult to treat, is particularly significant. These findings suggest that GHRH antagonists could be developed into new, effective clinical treatments, potentially offering options for patients with aggressive or hormone-refractory breast cancers. Future research should focus on validating these in vitro results in in vivo animal models and subsequently advancing to human clinical trials to assess safety and efficacy.